inclusion criteria: * male or female healthy subjects * body weight ≥ 50 kg for males and ≥ 45 kg for females * female subjects must meet the following criteria: not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy or ligation, or more than 1 year of amenorrhea), or of childbearing potential with a negative blood pregnancy test at screening, and willing to take strict and effective contraceptive measures (e.g., abstinence, medication, or barrier method \[e.g., contraceptive sponge, vaginal cuff, vaginal diaphragm, cervical cap, etc.\]) for 6 months after dosing. male subjects must agree to take strict and effective contraceptive measures (eg, abstinence, drug, or barrier method \[e.g., male condom\]) for 6 months after dosing. * results of medical evaluations, including physical examination, vital signs, laboratory tests, and other auxiliary examinations (chest imaging, abdominal b ultrasound, ecg, etc.) are normal or abnormal without clinical significance. * able to read and understand the contents of the trial, willing to participate in the trial and comply with the trial protocol and procedures, and having signed the written icf.

inclusion criteria: * male or female healthy subjects * body weight ≥ 50 kg for males and ≥ 45 kg for females * female subjects must meet the following criteria: not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy or ligation, or more than 1 year of amenorrhea), or of childbearing potential with a negative blood pregnancy test at screening, and willing to take strict and effective contraceptive measures (e.g., abstinence, medication, or barrier method \[e.g., contraceptive sponge, vaginal cuff, vaginal diaphragm, cervical cap, etc.\]) for 6 months after dosing. male subjects must agree to take strict and effective contraceptive measures (eg, abstinence, drug, or barrier method \[e.g., male condom\]) for 6 months after dosing. * results of medical evaluations, including physical examination, vital signs, laboratory tests, and other auxiliary examinations (chest imaging, abdominal b ultrasound, ecg, etc.) are normal or abnormal without clinical significance. * able to read and understand the contents of the trial, willing to participate in the trial and comply with the trial protocol and procedures, and having signed the written icf.

inclusion criteria: male or female healthy subjects body weight ≥ 50 kg for males and ≥ 45 kg for females female subjects must meet the following criteria: not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy or ligation, or more than 1 year of amenorrhea), or of childbearing potential with a negative blood pregnancy test at screening, and willing to take strict and effective contraceptive measures (e.g., abstinence, medication, or barrier method [e.g., contraceptive sponge, vaginal cuff, vaginal diaphragm, cervical cap, etc.]) for 6 months after dosing. male subjects must agree to take strict and effective contraceptive measures (eg, abstinence, drug, or barrier method [e.g., male condom]) for 6 months after dosing. results of medical evaluations, including physical examination, vital signs, laboratory tests, and other auxiliary examinations (chest imaging, abdominal b ultrasound, ecg, etc.) are normal or abnormal without clinical significance. able to read and understand the contents of the trial, willing to participate in the trial and comply with the trial protocol and procedures, and having signed the written icf.

inclusion criteria: male or female healthy subjects body weight ≥ 50 kg for males and ≥ 45 kg for females female subjects must meet the following criteria: not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy or ligation, or more than 1 year of amenorrhea), or of childbearing potential with a negative blood pregnancy test at screening, and willing to take strict and effective contraceptive measures (e.g., abstinence, medication, or barrier method [e.g., contraceptive sponge, vaginal cuff, vaginal diaphragm, cervical cap, etc.]) for 6 months after dosing. male subjects must agree to take strict and effective contraceptive measures (eg, abstinence, drug, or barrier method [e.g., male condom]) for 6 months after dosing. results of medical evaluations, including physical examination, vital signs, laboratory tests, and other auxiliary examinations (chest imaging, abdominal b ultrasound, ecg, etc.) are normal or abnormal without clinical significance. able to read and understand the contents of the trial, willing to participate in the trial and comply with the trial protocol and procedures, and having signed the written icf.